Alan R. Crossman
#148,686
Most Influential Person Now
Alan R. Crossman's AcademicInfluence.com Rankings
Alan R. Crossmanpsychology Degrees
Psychology
#3257
World Rank
#3694
Historical Rank
Cognitive Psychology
#385
World Rank
#399
Historical Rank
Download Badge
Psychology
Alan R. Crossman's Degrees
- Bachelors Psychology University of Oxford
Similar Degrees You Can Earn
Why Is Alan R. Crossman Influential?
(Suggest an Edit or Addition)Alan R. Crossman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Lesion of the subthalamic nucleus for the alleviation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced parkinsonism in the primate (1991) (536)
- Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease (2001) (460)
- Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1989) (445)
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease (2015) (346)
- Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease (2000) (321)
- Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study (2001) (321)
- Nucleus tegmenti pedunculopontinus: Efferent connections with special reference to the basal ganglia, studied in the rat by anterograde and retrograde transport of horseradish peroxidase (1983) (308)
- Primate models of dyskinesia: The experimental approach to the study of basal ganglia-related involuntary movement disorders (1987) (291)
- A hypothesis on the pathophysiological mechanisms that underlie levodopa‐ or dopamine agonist‐induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment (1990) (264)
- Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia. (1984) (207)
- Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate (1991) (205)
- Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease (1998) (196)
- Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease (2005) (195)
- A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease (2005) (191)
- Anatomical and electrophysiological studies on the reciprocal projections between the subthalamic nucleus and nucleus tegmenti pedunculopontinus in the rat (1983) (183)
- Neural mechanisms in disorders of movement. (1989) (182)
- Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections (2014) (180)
- Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea. (1988) (175)
- Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus (1985) (165)
- The projections from the parafascicular thalamic nucleus to the subthalamic nucleus and the striatum arise from separate neuronal populations: A comparison with the corticostriatal and corticosubthalamic efferents in a retrograde fluorescent double-labelling study (1994) (163)
- Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease (2002) (162)
- Effect of Repeated l -DOPA, Bromocriptine, or Lisuride Administration on Preproenkephalin-A and Preproenkephalin-B mRNA Levels in the Striatum of the 6-Hydroxydopamine-Lesioned Rat (1999) (162)
- Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease (2003) (161)
- On the Role of Enkephalin Cotransmission in the GABAergic Striatal Efferents to the Globus Pallidus (1994) (156)
- The efferent projections of the nucleus accumbens in the rat (1977) (141)
- Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson’s disease (2003) (140)
- Regional brain uptake of 2-deoxyglucose in N -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)—induced parkinsonism in the macaque monkey (1985) (132)
- A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. (1992) (130)
- The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease (1999) (125)
- Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus (1996) (124)
- Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate. (1992) (122)
- Basal ganglia and other afferent projections to the peribrachial region in the rat: A study using retrograde and anterograde transport of horseradish peroxidase (1981) (121)
- μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease (2001) (121)
- Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease (2000) (119)
- The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. (1989) (114)
- Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (1987) (113)
- Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers (1988) (110)
- Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. (1993) (109)
- Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. (1990) (107)
- Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia (2002) (107)
- Picrotoxin antagonism of γ aminobutyric acid inhibitory responses and synaptic inhibition in the rat substantia nigra (1973) (106)
- Identification of different subpopulations of neostriatal neurones projecting to globus pallidus or substantia nigra in the monkey: A retrograde fluorescence double-labelling study (1984) (104)
- Electrically excitable nerve cell bodies in the central ganglia of two insect species Periplaneta americana and Schistocerca gregaria. Investigation of cell geometry and morphology by intracellular dye injection (1971) (103)
- Neural mechanisms of dystonia: Evidence from a 2‐deoxyglucose uptake study in a primate model of dopamine agonist‐induced dystonia (1990) (102)
- Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat (1990) (100)
- Functional anatomy of movement disorders (2000) (99)
- The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease (2004) (93)
- MPTP-Induced Parkinsonism in the Monkey: Neurochemical Pathology, Complications of Treatment and Pathophysiological Mechanisms (1987) (89)
- Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease (2010) (88)
- Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan (2001) (84)
- Involvement of Sensorimotor, Limbic, and Associative Basal Ganglia Domains in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia (2005) (84)
- Convergent Synaptic Input From the Neostriatum and the Subthalamus Onto Identified Nigrothalamic Neurons in the Rat (1994) (84)
- Enhanced Preproenkephalin-B–Derived Opioid Transmission in Striatum and Subthalamic Nucleus Converges Upon Globus Pallidus Internalis in L-3,4-dihydroxyphenylalanine–Induced Dyskinesia (2007) (83)
- Phenotype of Striatofugal Medium Spiny Neurons in Parkinsonian and Dyskinetic Nonhuman Primates: A Call for a Reappraisal of the Functional Organization of the Basal Ganglia (2006) (83)
- The Cannabinoid Receptor Agonist WIN 55,212-2 Reduces D2, but Not D1, Dopamine Receptor-Mediated Alleviation of Akinesia in the Reserpine-Treated Rat Model of Parkinson's Disease (1997) (83)
- Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism (1993) (81)
- The organisation of the efferent projections of the zona incerta. (1985) (81)
- Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. (1989) (81)
- Subcortical changes in the regional uptake of [3H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma-aminobutyric acid antagonist into the subthalamic nucleus. (1985) (80)
- Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis) (1990) (79)
- Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus (1989) (77)
- Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey (1989) (77)
- The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography (1990) (76)
- Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease (2004) (76)
- Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: Relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake (1986) (76)
- Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high‐dose levodopa in the reserpine‐treated rat model of Parkinson's disease (2003) (75)
- Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-Treated Rat Model of Parkinson's Disease (2001) (74)
- Biology Takes Form. Animal Morphology and the German Universities, 1800-1900 (1996) (73)
- Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia (2004) (71)
- Thalamotomy for the alleviation of levodopa-induced dyskinesia: Experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey (1993) (71)
- Subthalamic projection to nucleus tegmenti pedunculopontinus in the rat (1981) (69)
- Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. (2004) (69)
- Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease (1995) (69)
- Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography (1985) (68)
- Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys (2001) (68)
- Induction of chorea and dystonia in parkinsonian primates (1990) (67)
- Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. (2001) (66)
- Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212‐2 (1996) (65)
- Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease (2018) (63)
- Non‐subtype‐selective opioid receptor antagonism in treatment of levodopa‐induced motor complications in Parkinson's disease (2004) (62)
- Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of γ-aminobutyric acid in the lateral segment of the globus pallidus (1991) (62)
- Problems associated with iontophoretic studies in the caudate nucleus and substantia nigra. (1974) (61)
- The effect of bicuculline on the gamma-aminobutyric acid (GABA) receptors of neurons of Periplaneta americana and Helix aspersa. (1971) (60)
- Antiparkinsonian Action of a δ Opioid Agonist in Rodent and Primate Models of Parkinson's Disease (2001) (59)
- Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease (2005) (58)
- Subthalamic nucleus efferent projection to the cerebral cortex (1981) (56)
- The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. (1999) (54)
- Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset (2003) (54)
- Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat (1992) (51)
- Striatal Proteomic Analysis Suggests that First L-Dopa Dose Equates to Chronic Exposure (2008) (51)
- Experimental hemiballismus in the baboon produced by injection of a gamma-aminobutyric acid antagonist into the basal ganglia (1980) (50)
- S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole (2004) (50)
- Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease (2011) (50)
- Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate (2004) (49)
- Microiontophoretic studies on the nature of the neurotransmitter in the subthalamo-entopeduncular pathway of the rat (1983) (47)
- Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease (1990) (46)
- Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. (2001) (46)
- Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (1989) (44)
- A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease (1994) (44)
- Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. (1996) (43)
- Experimental torticollis in the monkey produced by unilateral 6-hydroxydopamine brain lesions (1978) (43)
- The neurological basis of motor asymmetry following unilateral 6-hydroxydopamine brain lesions in the rat: the effect of motor decortication (1977) (43)
- Neurons projecting from the entopeduncular nucleus to the thalamus receive convergent synaptic inputs from the subthalamic nucleus and the neostriatum in the rat (1994) (42)
- d-[3H]aspartate and [14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents (1991) (41)
- Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease (2007) (41)
- Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: A proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE (2006) (40)
- Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. (2014) (38)
- The neurological basis of motor asymmetry following unilateral nigrostriatal lesions in the rat: the effect of secondary superior colliculus lesions (1978) (37)
- S33138 [N-[4-[2-[(3aS,9bR)-8-Cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo (2008) (37)
- In defence of optical density ratios in 2-deoxyglucose autoradiography (1984) (37)
- Electrophysiological studies on the axon pathways of specified nerve cells in the central ganglia of two insect species, Periplaneta americana and Schistocerca gregaria (1972) (37)
- Neuroanatomy : an illustrated colour text (2014) (36)
- [3H]‐2‐Deoxyglucose uptake study in mutant dystonic hamsters: Abnormalities in discrete brain regions of the motor system (1998) (35)
- Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus (2003) (34)
- Topographical Organization of Opioid Peptide Precursor Gene Expression Following Repeated Apomorphine Treatment in the 6-Hydroxydopamine-Lesioned Rat (1998) (33)
- MPTP: A neurotoxin producing a parkinsonian syndrome S.P. Markey, N. Castagnoli, A. J. Trevor andI. J. Kopin (eds). Academic Press, New York (1987) (33)
- A semi-quantitative atlas of 5-hydroxytryptamine-1 receptors in the primate brain (1986) (33)
- Further evidence for the stimulation of rat brain dopamine receptors by ergometrine (1974) (32)
- The neurological basis of striatally induced head-turning in the rat: The effects of lesions in putative output pathways (1980) (31)
- N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism. (1986) (31)
- Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. (2001) (30)
- Modulation of GABA Transmission by Diazoxide and Cromakalim in the Globus Pallidus: Implications for the Treatment of Parkinson's Disease (1996) (30)
- Modeling the functional organization of the basal ganglia. A parallel distributed processing approach (1991) (29)
- Kappa‐opioid receptor agonists increase locomotor activity in the monoamine‐depleted rat model of parkinsonism (1998) (29)
- Further evidence for the stimulation of rat brain dopamine receptors by a cyclic analogue of dopamine (1974) (28)
- Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia (2013) (25)
- Striatal AMPA Receptor Binding Is Unaltered in the MPTP-Lesioned Macaque Model of Parkinson's Disease and Dyskinesia (2002) (24)
- Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. (1998) (24)
- Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia (2014) (23)
- Regional changes in 2‐deoxyglucose uptake associated with neuroleptic‐induced tardive dyskinesia in the cebus monkey (1992) (23)
- Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway (1979) (23)
- Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets (2004) (22)
- Experimental choreoathetosis produced by injection of a gamma-aminobutyric acid antagonist into the lentiform nucleus in the monkey (1984) (21)
- Anatomic Localization of Dyskinesia in Children with “Profound” Perinatal Hypoxic-Ischemic Injury (2010) (20)
- RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease (2014) (20)
- Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. (1998) (19)
- Potential nondopaminergic drugs for Parkinson's disease. (2003) (19)
- Chemical signalling in the globus pallidus in parkinsonism. (1993) (18)
- An in vivo method for testing putative GABA-like compounds. (1980) (18)
- Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey (1991) (17)
- Proceedings: Pharmacological studies on single neurones in the substantia nigra of the rat. (1974) (17)
- Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA–induced dyskinesia (2021) (17)
- Comprar Crossman. Neuroanatomy, An Illustrated Colour Text 4th Edition | A. Crossman | 9780702030864 | Churchill Livingstone (2010) (16)
- TIMING OF LEVODOPA THERAPY: EVIDENCE FROM MPTP-TREATED PRIMATES (1987) (15)
- The effect of morphine on turning behaviour in rats and mice with unilateral 6-hydroxydopamine lesions [proceedings]. (1976) (14)
- Autoradiography of transferrin receptors in the human brain (1996) (14)
- Changes in dopamine D1 and D2 receptor binding in the substantia nigra following intrastriatal injection of a retrograde neurotoxin (volkensin) (1992) (13)
- Autoradiographic localization of dopamine D1 binding sites in areas receiving striatal input. (1987) (13)
- µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease (2020) (13)
- Basal Ganglia Mechanisms Mediating Experimental Dyskinesia in the Monkey (1987) (13)
- The role of the substantia nigra in a striatally-evoked motor response in the rat: effects of intranigral drugs and lesions (1981) (12)
- Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats. (2004) (11)
- The Subthalamic Nucleus: A More Complex Structure than Expected (1994) (11)
- Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors (2006) (11)
- Axon pathways of electrically excitable nerve cell bodies in the insect central nervous system. (1971) (10)
- Autoradiographic analysis of [3H]kainic acid binding in primate brain. (1987) (9)
- Cranial nerves and cranial nerve nuclei (2010) (8)
- Advances in the Understanding of Neural Mechanisms in Movement Disorders (1991) (8)
- The effects of narcotic analgesics on the turning behaviour of rats with 6-hydroxydopamine-induced unilateral nigro-striatal lesions (1980) (7)
- Receptor Changes in the Neocortex of Post-Mortem Tissue in Parkinson's Disease and Alzheimer's Disease (1992) (7)
- Acute and chronic behavioural sequelae resulting from intrastriatal injection of an NMDA agonist (1994) (7)
- Ventricular system and cerebrospinal fluid (2010) (7)
- Pathophysiology of dystonia. (1998) (7)
- Autoradiographic demonstration of binding sites for [3H]desipramine in rat brain (1982) (6)
- Cells of the nervous system (2010) (6)
- Picrotoxin antagonism of gamma-aminobutyric acid inhibitory responses and synaptic inhibition in the rat substantia nigra. (1973) (6)
- Autoradiographic demonstration of 5HT1 binding sites in the primate basal nucleus of Meynert. (1984) (6)
- Effects of manipulating pallidal and nigral GABA on striatally-mediated head-turning in the rat [proceedings]. (1977) (5)
- The Role of the Internal Segment of the Globus Pallidus in Mediating Dyskinesias (1994) (5)
- New Parallels Between Parkinson’s Disease and MPTP-Induced Parkinsonism in the Monkey (1987) (5)
- [Anatomo-physiologic substratum of akinesia in primates]. (1990) (4)
- Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1988) (4)
- On the role of endocannabinoids in L-DOPA-induced dyskinesia (1999) (4)
- Extracellular amino acid levels in the globus pallidus of the conscious primate studied by intracerebral microdialysis. (1989) (4)
- Effects of ergometrine on dopamine receptors. (1973) (4)
- Neuroanatomy for medical students 3rd edition (2005) (4)
- A lesioning and 2-deoxyglucose study of the hyperactivity produced by an intra-accumbens dopamine agonist (1985) (3)
- Effects of chronic morphine treatment on dopamine-mediated turning behaviour in rats and mice with 6-hydroxydopamineinduced unilateral nigro-striatal lesions (1980) (3)
- A remotely operated pump for intracerebral micro-injection in the primate (1983) (3)
- Blood supply of the central nervous system (2010) (2)
- Effects of intrapallidal administration of convulsant drugs on head-turning evoked by striatal stimulation in rats [proceedings]. (1978) (2)
- CCK Receptors and Brain Dopaminergic Systems (1988) (2)
- S33138 N -[4-[2-[(3 aS ,9 bR )-8-Cyano-1,3 a ,4,9 -tetrahydro[1]-benzopyrano[3,4- a Preferential Dopamine D 3 versus D 2 Receptor Antagonist and Potential Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral Characterization in Vivo (2008) (2)
- Anti-parkinsonian effects of EAA antagonists in the entopeduncular nucleus are due to an action at NMDA-like receptors (1990) (2)
- Localization of enkephalin mRNA in the monkey (1988) (2)
- Levetiracetam (keppra) potentiates the anti-dyskinetic action of amantadine in the MPTP-lesioned marmoset model of Parkinson's disease (2003) (2)
- Speculations on the Molecular Mechanisms Underlying Dopamine Agonist-Induced Dyskinesias in Parkinsonism (1996) (1)
- Crossman. Neuroanatomy, An Illustrated Colour Text 4th Edition (2010) (1)
- Effects of the novel histamine H3 receptor antagonist S 38093 in a non-human primate model of cognitive dysfunction (2009) (1)
- Functions of the basal ganglia—paradox or no paradox? (2016) (1)
- Effects of benzodiazepines and barbiturates in a GABA-dependent animal model: interactions with muscimol in the globus pallidus [proceedings]. (1979) (1)
- Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease (2001) (1)
- Non-Dopaminergic Approaches to the Treatment of Parkinson’s Disease (1994) (1)
- Enkephalin-Gaba Co-Transmission in the Striatopallidal Pathway in Parkinsonism (1994) (1)
- Antagonism of mu opioid receptors for the treatment of dyskinesias in Parkinson’s disease and other basal ganglia-related movement disorders. (2007) (0)
- Changes of mGluR5 mRNA expression levels in the basal ganglia of reserpine-treated rat model of parkinson's disease (2003) (0)
- Intracerebral injections of the EAA antagonist kyrairenate in the entopeduncular nucleus of the rat elicits a range of hyperkinetic disorders (1990) (0)
- Coverings of the central nervous system (2010) (0)
- The 5-HT1B/D receptor antagonist GR 127935 has anti-parkinsonian actions and potentiates the action of levodopa in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia (2003) (0)
- INTERACTION BETWEEN NMDA RECEPTOR ANTAGONISTS AND DOPAMINERGIC AGONISTS IN THE 6-HYDROXYDOPAMINE MODEL OF PARKINSON: CLUES FOR THERAPY (1992) (0)
- Dopamine D3 receptor levels following repeated dopaminergic treatment in the 6-OHDA-lesioned rat model of Parkinson's disease (2003) (0)
- Bezaed review dyskinesia 2015 progr neurobiol (2015) (0)
- The Role of Opioid Receptors in L-Dopa Induced Dyskinesia (2002) (0)
- Effects of the novel histamine H3 receptor antagonist S 38093 in a non-human primate model of cognitive dysfunction (2009) (0)
- Apparatus for measuring limb tonicity in the rat: application to the study of morphine-induced rigidity [proceedings]. (1980) (0)
- Dyskinesia treatment with 2,3-Benzodiazepines. (2003) (0)
- Reduced neurotensin binding in the substantia nigra following systemic MPTP administration (1986) (0)
- Use of compounds in the treatment of dyskinesia (2003) (0)
- A method for investigating neurotransmission in the basal ganglia using combined stimulation and intracerebral drug injection [proceedings]. (1977) (0)
- Blockade of kappa opiod receptors reduces L-DOPA-induced dyskinesia in the MPTP-lesioned rat model of Parkinson's disease (2003) (0)
- Peripheral nervous system (2010) (0)
- m Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson ’ s Disease (2020) (0)
- Sonic Hedgehog is a neuromodulator in the adult nucleus (2003) (0)
- Abnormalities of Striatal Nmda Receptor-Mediated Transmission in Parkinson’s Disease (2002) (0)
- Striatal NMDA receptor subunit abundance and phosphorylation in the dyskinetic MPTP-lesioned macaque model of Parkinson's disease and dyskinesia (2003) (0)
- Cerebral hemisphere and cerebral cortex (2010) (0)
- P2.010 Progressive MPTP non-human primate models that recapitulate non-motor symptoms of Parkinson's disease (2009) (0)
- Symposium on neurobiology of the basal ganglia (2000) (0)
- 2.447 AMPA antagonists attenuate L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat model of Parkinson's disease (2007) (0)
- Hypothalamus, limbic system and olfactory system (2010) (0)
- NOVEL AGONISTS FOR THE DOPAMINE D 3 RECEPTOR SUBTYPE WITH HIGH IN VIVO ACTIVITY (2012) (0)
- Theorganisation oftheefferent projections ofthezonaincerta (1985) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alan R. Crossman?
Alan R. Crossman is affiliated with the following schools:
